Efficacy and tolerability of a combination treatment of memantine and donepezil for alzheimer's disease: A literature review evidence

European Neurological Journal

Volumn 3, Issue 1, 2011, Pages 15-19

  Riverol, Mario ^a,b   Slachevsky, Andrea ^c,d   López, Oscar L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF CHILE   (Chile)

^d UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Combined therapy; Donepezil; Memantine

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; COMBINATION CHEMOTHERAPY; CONFUSION; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 80655146393     PISSN: 20418000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Evans DA, Funkenstein HH, Albert MS. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989;262(18):2551-2556.
2. Fitzpatrick AL, Kuller LH, Ives D, et al. Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc. 2004;52 (2):195-204.
3. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
4. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von Strauss E, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health. 1998;88(10):1452-1456.
5. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1-134.
6. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15.
7. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50(1): 136-145.
8. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD. A sixmonth, randomized, placebo-controlled trial with a six-month extension. Neurology. 2000;54:2261-2268.
9. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000;321(7274):1445-1449.
10. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318(7184):633-638.
11. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease. Arch Neurol. 2004;61:1852-1856.
12. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057-1065.
13. Black SE, Doody RS, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007; 69:459-469.
14. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433.
15. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-lab study. Enru Neuropsychopharmacol. 2000;10(3): 195-203.
16. Farlow MR, Lilly ML. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr. 2005;5:3.
17. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004;61(2):252-256.
18. Holmes C, Wilkinson D, Dean C, et al. The efficacy of denepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214-219.
19. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimers' disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005; 3(3):137-148.
20. O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology [published online ahead of print November 18, 2010]. J Psychopharmacol. 2010.
21. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003;9(3):275-308.
22. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715.
23. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97-107.
24. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
25. van Dyck CH, Tariot P, Meyers BS, Maica-Resnick E. A 24-week randomized controlled trial of memantine in patients with moderateto-severe Alzheimer's disease. Alzheimer Dis Assoc Disord. 2007;21(2): 136-143.
26. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-27.
27. Lanctot KL, Rajaram RD, Herrmann N. Therapy for Alzheimer's disease: how effective are current treatments? Ther Adv Neurol Disord. 2009; 2(3):163-180.
28. Epstein NU, Saykin AJ, Risacher SL, Gao S, Farlow MR. Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. Drugs Aging. 2010;27(8):677-686.
29. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol. 2003;18(2):81-85.
30. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil. JAMA. 2004;291(3): 317-324.
31. van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006;14(5):428-437.
32. Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord. 2006;20(4):255-262.
33. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderateto-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006;20(4):263-268.
34. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57-63.
35. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89.
36. Jones R, Sheehan B, Phillips P, et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease-a multicentre RCT. Trials. 2009;10:57.
37. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-221.
38. Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68(1):58-66.
39. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600-607.
40. Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin. 2007;23(5):1187-1197.